Eric Lefkofsky’s Post

View profile for Eric Lefkofsky, graphic

Founder and CEO at Tempus, Inc.

We have been unwavering in our conviction that RNA data is key to the development of personalized treatments, which is why we have been sequencing RNA since the very beginning. Receiving a PLA code from AMA for the PurIST test is a meaningful step forward in carving a path for reimbursement for these kinds of RNA-based tests.

View organization page for Tempus AI, graphic

82,655 followers

We’re excited to announce that our PurIST℠ algorithmic test has received a proprietary laboratory analysis (PLA) code from the American Medical Association (AMA). The new code will be effective on October 1, 2024. The PurIST℠ PLA code is the first common procedural terminology (CPT) code created to describe an algorithm-only analysis from previously-sequenced, laboratory developed test (LDT), transcriptomic (RNA) data, representing a meaningful step towards reimbursement for AI-enabled algorithms. Learn more: https://tempus.co/3zx5QmZ

  • No alternative text description for this image
Kelly Gordon, PhD, MB(ASCP), RAC-Devices

CEO @ Boudicca Dx | Precision Medicine Consulting | Regulatory Professional | Clinical Biomarker Development | Companion Diagnostics | IVD Product Development | Clinical Molecular Technologist (LDTs) | Scientific Advisor

4mo

Could not agree more and so much more to come for RNA-based diagnostics! RNA has already proven its value for fusion detection, innovative prognostic and predictive signature development and offers a comprehensive solution for expression biomarkers maximizing tissue use. I am excited to see what cfRNA liquid biopsy will unveil-so much yet to discover in the blood! 🩸

Like
Reply
Wesley Sukdao

CEO @ Proteotype | Dad | On a Mission

4mo

Very cool, and well done

Like
Reply
Andrei Naeymi-Rad

VP Corporate Strategy at Intelligent Medical Objects

4mo

Huge win for Tempus AI!

Like
Reply
Rich Langdale

Founder at NCT Ventures and Partner in Health 2047

4mo

Totally agree on this aproach!

Like
Reply
Kari Kaplan, MS, LCGC

Molecular diagnostic product leader | Genomic Science Liaison | Expertise in clinical genetics and driving the success of innovative, molecular diagnostic tests and services.

4mo

Congrats! PLA codes are no easy feat.

Like
Reply
Sara Brown, Ph.D

Vice President, Head of Marketing at Integrated DNA Technologies, a Danaher Company

4mo

Exciting development, congrats!

Like
Reply
Vibhuti Ranjan Singh

Product Officer | Growth & Innovation in B2B SaaS, AI | ex - eBay, GE, EY

4mo

That is very inspiring Eric!

Like
Reply
Vivek Das, PhD, M.Sc.

Lead Data Scientist @ Novo Nordisk | Integrated Omics in Clinical Trials | Computational Systems Biology | Data Science I Applied ML/AI | Strategy & Innovation | Mentor | Thought Leader | Scientific Advisory Board Member

4mo

Congratulations 🎉

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics